Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
Quarterly results
Edesa Biotech, Inc. (SBOT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Edesa Biotech Reports Fiscal Third Quarter 2023 Results"
02/10/2023 8-K Quarterly results
Docs: "Edesa Biotech Reports Fiscal 1st Quarter 2023 Results"
12/16/2022 8-K Quarterly results
Docs: "Edesa Biotech Reports Fiscal Year 2022 Results"
08/12/2022 8-K Quarterly results
Docs: "Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results"
02/14/2022 8-K Quarterly results
Docs: "Edesa Biotech Reports Fiscal 1st Quarter 2022 Results"
12/28/2021 8-K Quarterly results
Docs: "Edesa Biotech Reports Fiscal Year 2021 Results"
12/07/2020 8-K Quarterly results
Docs: "Edesa Biotech Reports Fiscal Year 2020 Results"
05/08/2019 8-K Quarterly results
Docs: "Financial Results"
02/05/2019 8-K Quarterly results
11/30/2018 8-K Quarterly results
Docs: "Exhibit 99.1stellar Biotechnologies Reports Fiscal Year 2018 Financial Results LOS ANGELES, Nov. 30, 2018 /PRNewswire/ -- Stellar Biotechnologies, Inc. , a leading manufacturer of a key protein utilized in multiple immunotherapy and immuno-oncology development pipelines, today reported financial results for the fiscal year ended September 30, 2018 and provided an update on its business. During fiscal year 2018, Stellar advanced a number of technical, operational and strategic initiatives, including an infrastructure project that will allow the company to rapidly expand aquaculture production systems for its Stellar KLH products. In fiscal 2018, Stellar also reported positive research results from viral clearance and glycosylation studies associated with its manufacturing scale-up initiativ..."
08/08/2018 8-K Quarterly results
Docs: "Financial Results"
05/07/2018 8-K Quarterly results
Docs: "Financial Results"
02/07/2018 8-K Quarterly results
Docs: "Financial Results"
12/01/2017 8-K Quarterly results
Docs: "Financial Results for the Fiscal Year Ended September 30, 2017"
08/09/2017 8-K Quarterly results
05/09/2017 8-K Form 8-K - Current report
02/06/2017 8-K Form 8-K - Current report
12/14/2016 8-K Form 8-K - Current report
08/09/2016 8-K Form 8-K - Current report
05/09/2016 8-K Quarterly results
Docs: "Stellar Biotechnologies Reports Second Quarter 2016 Financial Results and Operational Highlights"
02/08/2016 8-K Form 8-K - Current report
12/14/2015 8-K Quarterly results
Docs: "Stellar Biotechnologies Reports Fiscal Year-End 2015 Financial Results and Operational Highlights"
08/10/2015 8-K Quarterly results
Docs: "Stellar Biotechnologies Reports Third Quarter 2015 Financial Results and Operational Highlights"
05/11/2015 8-K Quarterly results
Docs: "Stellar Biotechnologies Reports Second Quarter 2015 Financial Results"
02/10/2015 8-K/A Quarterly results
Docs: "Stellar Biotechnologies Reports First Quarter 2015 Financial Results"
02/09/2015 8-K Quarterly results
Docs: "Stellar Biotechnologies Reports First Quarter 2015 Financial Results"
11/13/2014 8-K Quarterly results
Docs: "Stellar Biotechnologies Reports Year-End 2014 Financial Results Company to Hold Conference Call at 1:30 p.m. ET Today PORT HUENEME, CA-- - Stellar Biotechnologies, Inc. , the leader in sustainable manufacture of Keyhole Limpet Hemocyanin , an important immune-stimulating protein used in wide-ranging immunotherapeutic markets, has reported preliminary financial results for the year ended August 31, 2014. Fiscal Year Ended August 31, 2014 Results:"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy